T2 Biosystems, Inc. (TTOO)

Market Cap	87.59M
Revenue (ttm)	7.18M
Net Income (ttm)	-45.65M
Shares Out	15.37M
EPS (ttm)	-11.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	172,757
Open	5.65
Previous Close	5.64
Day's Range	5.38 - 5.78
52-Week Range	2.60 - 70.00
Beta	0.10
Analysts	Hold
Price Target	5.00 (-11.35%)
Earnings Date	May 6, 2024

About TTOO

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnosti...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Aug 7, 2014
• Employees: 113
• Stock Exchange: NASDAQ
• Ticker Symbol: TTOO

Financial Performance

In 2023, T2 Biosystems's revenue was $7.19 million, a decrease of -67.75% compared to the previous year's $22.31 million. Losses were -$50.08 million, -19.66% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for TTOO stock is "Hold." The 12-month stock price forecast is $5.0, which is a decrease of -11.35% from the latest price.

Price Target

$5.0

(-11.35% downside)

Analyst Consensus: Hold